FibroGen
Discovers, develops, and commercializes therapeutic agents to treat serious unmet medical needs.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor investor investor investor investor investor | €0.0 | round |
| investor investor investor investor investor investor investor investor investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
* | $75.0m | Post IPO Debt | |
| Total Funding | 000k | ||
| USD | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | 63 % | 20 % | (31 %) | 33 % | (40 %) | 5 % | (80 %) |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (32 %) | (29 %) | (106 %) | (123 %) | (208 %) | (168 %) | (415 %) |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (41 %) | (30 %) | (107 %) | (123 %) | (209 %) | (192 %) | (161 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 111 % | 82 % | 143 % | 164 % | 211 % | 191 % | 323 % |
Source: Company filings or news article
Related Content
FibroGen is a biopharmaceutical company focused on developing innovative therapies for serious and life-threatening diseases such as anemia, fibrosis, and cancer. The company operates in the global healthcare market, with a significant presence in China. FibroGen's business model revolves around research and development (R&D) of novel drugs, conducting clinical trials, and bringing these therapies to market upon regulatory approval. The company primarily serves patients suffering from chronic and severe conditions, aiming to improve their quality of life through advanced medical treatments. Revenue is generated through the commercialization of approved drugs and strategic partnerships with other pharmaceutical companies. FibroGen's pipeline includes promising candidates like Roxadustat for anemia and Pamrevlumab for fibrosis and cancer, which are currently in various stages of clinical trials. The company is committed to responsible development and ethical practices, ensuring that their groundbreaking therapies reach those who need them the most.
Keywords: biopharmaceutical, anemia, fibrosis, cancer, clinical trials, R&D, innovative therapies, global healthcare, Roxadustat, Pamrevlumab